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Summary
By positional cloning, we identified two breakpoint-spanning genes in a familial clear cell renal cell carcinoma (CCRCC)-
associated t(1;3)(q32.1;q13.3): LSAMP and NORE1 (RASSF1 homolog). Both genes are downregulated in 9 of 9 RCC cell
lines. While the NORE1A promoter predominantly presents partial methylation in 6 of the cell lines and 17/53 (32%) primary
tumors, the LSAMP promoter is completely methylated in 5 of 9 cell lines and in 14/53 (26%) sporadic and 4 familial
CCRCCs. Expression of LSAMP and NORE1A proteins in CCRCC cell lines inhibited cell proliferation. These characteristics
indicate that LSAMP and NORE1A may represent new candidate tumor suppressors for CCRCC.
Introduction scribed by Cohen et al. (1979). To date, at least eight such
hereditary CCRCC-related chromosomal translocation families
have been reported (Cohen et al., 1979; Kovacs and Hoene,Renal carcinoma is known to have different histological types
with distinct genetic profiles (Storkel et al., 1997). Worldwide, 1988; Kovacs et al., 1989; Koolen et al., 1998; Podolski et al.,
2001; Kanayama et al., 2001). Interestingly, translocation in allapproximately 150,000 people are diagnosed with renal carci-
noma, resulting in 78,000 deaths annually (Zbar et al., 2003). The these CCRCC families is linked to chromosome 3, making con-
stitutional chromosome 3 translocation a predisposing factormost common type is clear cell renal cell carcinoma (CCRCC).
Studies of familial CCRCC have led to the identification of impor- (van Kessel et al., 1999; Bodmer et al., 1998, 2002c). The subse-
quent observation of the loss of translocation derivative chromo-tant tumor suppressor genes such as VHL (Latif et al., 1993).
Recently, position cloning also resulted in the discovery of other some 3 (der(3) chromosome) and somatic VHL mutations in a
proportion of familial tumors led to the proposal of a three-stepkidney cancer-related genes, BHD, FH, and HRPT2 (Nickerson
et al., 2002; Tomlinson et al., 2002; Carpten et al., 2002). While model of CCRCC tumorigenesis (Schmidt et al., 1995; Bodmer
et al., 1998, 2002c): initial constitutional chromosome 3 translo-hereditary CCRCCs are mainly attributed to VHL mutations,
there are known CCRCC families and a significant proportion cation, subsequent somatic loss of the der(3) chromosome lead-
ing to the loss of a copy of VHL, and a third hit in the form ofof sporadic CCRCCs that are not associated with the VHL (Teh
et al., 1997; Woodward et al., 2000), thus pointing to the exis- random somatic mutation in the second VHL allele. However,
loss of the der(3) chromosome was observed only in a subsettence of other CCRCC-related genes. Because some CCRCC
families are associated with balanced chromosomal transloca- of the examined samples. Most of the analyzed familial tumors
with loss of the der(3) did not carry VHL mutations. Furthermore,tions, the translocation breakpoint-spanning genes are likely
CCRCC-related candidate genes. The first CCRCC family with neither der(3) loss nor VHL mutations were observed in several
tumor biopsies in the affected families (Eleveld et al., 2001;a balanced chromosomal translocation t(3;8)(p14;q24) was de-
S I G N I F I C A N C E
Identification of familial CCRCC genes such as the VHL tumor suppressor gene (TSG) has provided important insights into the
pathogenesis of hereditary and sporadic tumors. Here we demonstrate that LSAMP and NORE1 are the breakpoints of a familial
CCRCC-related t(1;3) and that the expression of these genes is downregulated in RCC cell lines and sporadic CCRCCs. LSAMP has
no known activities in cancer, but Nore1 is a Ras effector. Further investigations of LSAMP and NORE1 may lead to the elucidation
of novel mechanisms of tumorigenesis.
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Figure 1. Mapping of the t(1;3) breakpoints on chromosomes 1q32.1 and 3q13.3 by FISH and Southern blot analysis
A: A contig of nine BAC clones in a 3.6 cM region of 1q32.1 was constructed (left panel). The RP11-54L22 was first found to span the breakpoint by FISH
split assay. Overlapped BAC clones (CTD-2245C1, -2321B11, and -2278G17) also showed split signals and confine the der(1) breakpoint region to about 30
kb (dotted box). Similarly, a contig of ten BAC clones within a 5 cM region of 3q13.3 was established (right panel); and the breakpoint was found within
RP11-281N16 and was further mapped to an about 30 kb region (dotted box) using overlapping clones (RP11-149B11, CTD-2246M24, and -2514L8).
B: Fine mapping of the 1q32.1 and 3q13.3 breakpoints by Southern blot analysis and restriction mapping. Fifteen specific DNA probes (4–10 kb) flanking
the 1q and 3q breakpoints were synthesized by long-range PCR with specific primers from known sequence RP11-54L22 and -281N16. Southern blot analyses
showed that a 5.6 kb 1q-p4 probe (left panel) and a 6.2 kb 3q-p2 probe (right panel) span the respective 1q32.1 and 3q13.31 breakpoints, which narrowed
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Bodmer et al., 2002b). These observations suggest that the nome sequence databases and BAC clone databases, we de-
signed several sets of specific primers around the breakpointsbreakpoint-spanning genes in the familial RCC-associated
chromosome 3 translocations are also likely implicated in RCC and performed long-range PCR to amplify the breakpoint frag-
ments (Figure 2A). A 2.15 kb der(1) breakpoint and a 3.25 kbtumorigenesis or act synergistically in the above model in the
form of genetic and/or epigenetic alterations. der(3) breakpoint were amplified and subcloned into TA-cloning
vector (Invitrogen) (Figure 2A). Subsequent DNA sequencing ofAnalysis of the constitutional t(3;8)(p14;q24) translocation
associated with familial CCRCC led to the identification and the breakpoint fragments resulted in the identification of both
breakpoints (Figure 2; also see Table S1 of the Supplementalextensive investigation of the breakpoint-spanning gene FHIT
(fragile histidine triad) on 3p14 (Ohta et al., 1996). FHIT is thought Data at http://www.cancercell.org/cgi/content/full/4/5/405/DC1).
The cloning of the breakpoints led to the identification ofto be a putative tumor suppressor gene, and aberrant FHIT
transcripts and FHIT genomic lesions were observed in a variety two breakpoint-spanning genes, NORE1 on 1q32.1 and LSAMP
on 3q13.3 (Figure 2B). To investigate whether fusion proteinsof primary tumors and tumor-derived cell lines (Ohta et al.,
1996; Siprashvili et al., 1997; Druck et al., 1997). The partner resulting from the chromosome translocation are involved in
tumorigenesis of CCRCC, we carried out Northern blot analysisbreakpoint-spanning gene TRC8 on the chromosome 8 shows
high homology to the Drosophila patched (PTCH) gene and and RT-PCR to detect any fusion transcript of NORE1 and
LSAMP (see Table S1 on Cancer Cell website). No detectableprobably also functions as a tumor suppressor (Gemmill et al.,
2002). Also, another two breakpoint-spanning genes, DIRC1 on fusion transcripts were found in the FRCC3 and FRCC5 cell
lines from two patients in the t(1;3) family. We also tested thechromosome 2q33 and DIRC2 on 3q21, disrupted, respectively,
in t(2;3)(q33;q21) and t(2;3)(q35;q21) breakpoints, have been possible sequence combination from NORE1 and LSAMP. Be-
cause NORE1 lies in the positive DNA strand and LSAMP inidentified (Druck et al., 2001; Bodmer et al., 2002a). The role of
these genes in CCRCC tumorigenesis remains to be deter- the reverse strand, there is little likelihood for them to form any
NORE1-LSAMP or LSAMP-NORE1 fusion proteins.mined.
Here we described the positional cloning of the t(1;3) Given the association between chromosome 3 transloca-
tions and CCRCC susceptibility (van Kessel et al., 1999; Bodmer(q32.1;q13.3) chromosomal breakpoints and the identification
of two breakpoint-spanning genes, LSAMP (limbic system- et al., 2002c), we next investigated the gene LSAMP. LSAMP
is composed of seven exons and is disrupted in intron 2 by theassociated membrane protein gene) on 3q13.3 and NORE1 on
1q32.1 in a previously reported Japanese hereditary CCRCC breakpoint (Figure 2B). To elucidate whether genetic changes
in LSAMP play a role in CCRCC, we performed LSAMP mutationfamily (Kanayama et al., 2001). LSAMP encodes a neuronal
surface glycoprotein that belongs to the IgLONs (immunoglobu- analysis in 9 CCRCC cell lines and in 53 sporadic and 4 familial
tumors. No LSAMP mutation was detected. However, epige-lin LSAMP, OPCML/OBCAM, and neurotrimin) family and is
distributed in cortical and subcortical regions of the limbic sys- netic silencing in association with hypermethylation, the most
common form of inactivation for many tumor suppressor genestem (Pimenta et al., 1996). To date, very little is known about
LSAMP and its biological role remains unclear. However, its (Jones and Baylin, 2002), could still occur. First, by RT-PCR,
we found that LSAMP was downregulated in all 9 RCC cell linesfamily partner gene OPCML/OBCAM on 11q25 was recently
found to be epigenetically inactivated and was regarded as a (Figure 3A). We further demonstrated that the LSAMP promoter
was methylated in 7/9 CCRCC cell lines (78%), 14/53 sporadiccandidate TSG in epithelial ovarian cancer (Sellar et al., 2003).
NORE1 was recently identified as a homolog of the tumor sup- CCRCCs (26%), and all 4 familial CCRCCs tumors from the t(1;3)
family (Figure 3B). In association with the promoter-methylationpressor gene RASSF1 at 3p21.3, which is frequently inactivated
via promoter hypermethylation in a variety of human tumors status, LSAMP expression in ten examined tumors with LSAMP-
promoter methylation was also downregulated (Figure 3A). Of(Dammann et al., 2000; Tommasi et al., 2002). The mouse coun-
terpart Nore1 is a Ras effector (Vavvas et al., 1998). the LSAMP-promoter-methylated cell lines and tumors, all pre-
sented complete methylation except two cell lines and one spo-
radic tumor. Furthermore, in the four familial tumors (FT1 toResults and Discussion
FT4), one LSAMP allele was breakpoint disrupted followed by
the loss of the der(3) chromosome shown in our previous studyWe have previously mapped the constitutional t(1;3)-associated
breakpoints to bands 1q32.1 and 3q13.3 in a family with four (Kanayama et al., 2001), and the other copy was hypermethyl-
ated (Figure 3B), implying that LSAMP may undergo bi-alleliccases of CCRCC (Kanayama et al., 2001). In this study, we
cloned the breakpoints of t(1;3)(q32.1;q13.3) by using a strategy inactivation. These observations suggest that LSAMP may be
involved in CCRCC, though further functional studies arethat combined FISH, Southern blot, long-range PCR, and DNA
sequencing. FISH experiments enabled us to narrow the needed to elucidate its mechanism.
The 1q32.1 breakpoint-disrupted gene, NORE1, also ap-breakpoint regions to a 20 to 30 kb range on both affected
chromosomes (Figure 1A). These were further refined via South- peared to be an excellent candidate CCRCC suppressor gene.
NORE1 undergoes alternative splicing, resulting in two isoforms,ern blot analyses and restriction mapping to approximately 2 kb
(Figures 1B and 1C). Assisted by information from human ge- NORE1A and NORE1B. The breakpoint disrupted both NORE1A
both breakpoint regions to approximately 6 kb. Restriction mapping refined the 1q and the 3q breakpoints to about 1.5 kb (left panel) and 2 kb regions,
respectively (right panel).
C: Representative Southern blot analyses from both chromosomes showing distinct aberrant bands (indicated by arrowheads) after restriction digestion.
DNA from two normal controls (N1, N2) and two patients (FRCC3 and FRCC5) were completely digested and subjected to DNA hybridization analysis.
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Figure 2. Cloning of both der(1) (1q32.1) and der(3) (3q13.31) breakpoints through long-range PCR and DNA sequencing
A: Amplification of der(1) and der(3) breakpoints via long-range PCR. A 2.15 kb der(1) breakpoint fragment (der(1)-BP) and a 3.25 kb der(3) breakpoint
fragment (der(3)-BP) were amplified. The breakpoint fragments were sequenced and are shown in the lowest boxes. The normal sequences around the
breakpoints on 1q32.1 and 3q13.31 are also shown for comparison. The uppercase sequences are from 1q32.1 and the lowercase sequences are from
3q13.31. The sequences in red on 3q13.31 are deleted from the breakpoints.
B: Schematic illustration of the identification of breakpoint-spanning genes. The translocation breakpoints occur within intron 2 of both breakpoint-spanning
genes LSAMP at 1q32.1 and NORE1 at 3q13.31; this is accompanied by loss of 52 or 54 bp (red sequences in panel A) from LSAMP and of 2 or 0 bp from
NORE1. An insertion of nucleotide G (ins G) in the breakpoint junction and a loss of 2 bp (delTG) in LSAMP in the distal part of breakpoint were also observed.
NORE1 has two isoforms, NORE1A and NORE1B. LSAMP contains seven exons and sits in the reverse strand of chromosome 3.
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and NORE1B (Figure 2B). NORE1 is homologous to a family of Kanayama et al., 2001). Considering the complexity of the
multistep process in tumorigenesis, the possibility exists thatRAS binding proteins, including RASSF1, rat Maxp1, and murine
the breakpoint-disrupted genes, especially LSAMP, may con-Nore1 (Vavvas et al., 1998; Dammann et al., 2000; Vos et al.,
tribute to the occurrence of familial tumors by acting as compo-2000; Ortiz-Vega et al., 2002; Tommasi et al., 2002) that have
nents in the three-step model of tumorigenesis of hereditarybeen proposed to be effectors for the small GTPase or Ras.
CCRCC. We have previously demonstrated that four examinedNore1 and RASSF1 have been shown to induce apoptosis (Vos
familial CCRCC tumors lost the der(3) chromosome and two of2000; Khokhlatchev et al., 2002). Other studies, however, have
them carry VHL mutations, supporting the three-step model ofshown that Nore1 family members are cytostatic and modulate
tumorigenesis (Kanayama et al., 2001). Here, we supplementcyclin D1 levels, thereby influencing the activity of cell cycle-
this model with our LSAMP and NORE1A data. The constitu-dependent kinases (Khokhlatchev et al., 2002). RASSF1 maps
tional translocation t(1q;3q) and disruption of a copy each ofto 3p21, a region of frequent loss of heterozygosity (LOH) in
LSAMP and NORE1, as the first set of steps of tumorigenesis,CCRCC (van den Berg and Buys, 1997; Dammann et al., 2000),
act as the predisposing factors in development of CCRCC.and this gene has recently been shown to be epigenetically
The translocation also results in the increased susceptibility toinactivated in kidney cancer (Dreijerink et al., 2001; Morrissey et
somatic loss of the chromosome der(3). The following nondis-al., 2001; Yoon et al., 2001). Thus, we proceeded to investigate
junctional loss of der(3) deletes a copy each of the RCC-relatedNORE1 as a candidate RCC suppressor.
genes in chromosome 3 (e.g., VHL, RASSF1A), which furtherSimilarly, we performed mutation screening and methylation
increases the predisposition to CCRCC. This second set ofanalysis on NORE1 in all the RCC cell lines and tumors. Two
steps will accelerate the transformation process and cellularalterations, GTG(Val189)ATG(Met189) and CGG(Arg248)
growth, leading to the third set of steps involving either theCAG(Gln248), were identified (see Supplemental Figure S2 on
inactivation of the other VHL allele (e.g., somatic mutation) or theCancer Cell website). The former was present in 5% of the 100
genetic/epigenetic alterations in other CCRCC-related genes,tested normal subjects, whereas the latter was not found in any
including LSAMP, in the remaining copy of chromosome 3.of them. As both were also present in the matched normal
These factors may act synergistically and finally lead to thekidney tissues, it is likely that they represent polymorphisms.
occurrence of CCRCC.We then perceived that NORE1A expression was also downreg-
Epigenetic inactivation of these genes can be reversed byulated in the 9 RCC cell lines, and the NORE1A promoter was
demethylation treatment with the DNA methylation inhibitormethylated in 6/9 RCC cell lines and 17/53 (32%) sporadic
5-aza-2-deoxycytidine (5-aza-CdR). The demethylation treat-
RCC tumors (Figures 3A and 3C), whereas methylation in the
ment resulted in significantly increased expression of LSAMP
NORE1B promoter was detected only in RCC cell lines A-498
and NORE1 in eight cell lines (Figure 3A), indicating that repres-
and A-704. NORE1A expression in examined 10 of the 17 af- sion is at least in part mediated by methylation.
fected tumors was also downregulated (Figure 3A). Two normal Finally, to further evaluate the role of LSAMP and NORE1 as
kidney control samples (N3 and N44) also showed NORE1A tumor suppressor candidates in cancer, enhanced green fluores-
promoter methylation at lower extents compared with their cent protein EGFP-LSAMP, -NORE1A, and -Nore1 expression
matched tumors (3T and 44T), probably due to contamination plasmids were microinjected or transfected into two RCC cell
from the tumor tissues. Interestingly, NORE1A-promoter meth- lines, A-498 and/or Caki-1, in which the LSAMP and NORE1A
ylation does not overlap with LSAMP-promoter methylation ex- promoters were methylated. Cells were then counted at indi-
cept in four tumors. These results suggest that NORE1A may cated times and were monitored for cell number and/or prolifera-
be also associated with sporadic CCRCC. Yet, unlike the meth- tion. Alternatively, cells were monitored by epi-fluorescence/
ylation situation in LSAMP, only 1/4 hereditary tumors showed phase-contrast microscopy to evaluate proliferation, fluroes-
even slight NORE1A promoter methylation, indicating that one cent protein expression, or apoptosis. While cells expressing
wild-type allele of NORE1A still exists in these hereditary tumors. EGFP continued to proliferate at rates similar to those of unin-
Whether NORE1A undergoes haploinsufficiency in tumorigene- jected neighbors, cells expressing EGFP-LSAMP, -NORE1A,
sis remains indeterminate. and -Nore1 failed to grow (Figure 4B). There was no evidence
In addition, 7/14 tumors (50%) with LSAMP-promoter meth- of apoptosis in any of the experiments. This growth inhibition
ylation showed LOH of the LSAMP locus. However, LOH was role was also demonstrated in 293-T cells stably transformed
also observed in 17/39 tumors (44%) without LSAMP-promoter with an inducible Nore1 gene by lipid-mediated transfection
methylation. Similar LOH results were obtained on NORE1A (see Supplemental Figure S3c on the Cancer Cell website).
(methylated, 5/17 [29%]; unmethylated, 8/36 [22%]), indicating We also observed that EGFP-LSAMP seemed to be cyto-
that the LOH may be correlated with CCRCC tumorigenesis but plasmic, and EGFP-NORE1A appeared in both cytosol and nu-
is not methylation dependent. cleus. EGFP-Nore1 was predominantly nuclear and tended to
Promoter methylation in both LSAMP and NORE1A may occupy discrete puncta within the nucleus (Figure 4A). This was
also be linked to other types of cancers. NORE1A-promoter observed in both formaldehyde-fixed and living cells; thus, the
methylation has recently been detected in cancer cell lines and localization was unlikely to be due to a fixation artifact. Further-
in 24% NSCLC (Hesson et al., 2003). Here we found that the more, the nuclear localization of EGFP-Nore1 was also con-
LSAMP promoter was methylated in 5/19 (26%) colorectal can- firmed in the transfected Caki-1 RCC cell line and in the 293-T
cers. cells by nuclear fractionation (see Supplemental Figures S3a
The exact role of these genes in tumorigenesis is unclear. and S3b online).
In the familial cases, however, the underlying mechanism is still Our observations are consistent with a growth suppression
the three-step model of chromosome 3 translocation-related role for LSAMP, NORE1A, and Nore1. Also, despite the pres-
ence of a putative Ras-association region, our results suggesthereditary CCRCC tumorigenesis (Bodmer et al., 1998, 2002c;
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Figure 3. Lower expression and promoter methylation of LSAMP and NORE1A in RCC cell lines and sporadic RCC tumors
A: The expression of LSAMP and NORE1A in nine RCC cell lines and sporadic tumors (LSAMP: 0.06  0.06 for cell lines and 0.05  0.07 for tumors; NORE1A:
0.19  0.10 for cell lines and 0.27  0.12 for tumors) is significantly lower than that in nine normal kidney tissues (LSAMP: 0.77  0.28; NORE1A: 1.03  0.53)
using real-time PCR assay (t test of SSPS, p  0.001). Right panel, eight RCC cell lines were demethylated using 5-aza-CdR and the expression of both
LSAMP and NORE1A was significantly increased in each line (LSAMP: untreated, 0.35  0.23; 5-aza-CdR, 1.02  0.33; NORE1: untreated, 0.03  0.02; 5-aza-
CdR, 0.24  0.10) (t test of SSPS, p  0.001).
B: Methylation analysis of the LSAMP promoter. Bisulfite-treated DNA from 53 matched pairs of human CCRCC tumors and normal DNA samples, 9 RCC
cell lines, 2 t(1;3)-positive lymphoblastoid cell lines, and 2 control lymphoblastoid cell lines (NC1 and NC2) were amplified and digested with HhaI. The
LSAMP promoter (540 bp) contains 28 CpG islands. The analyzed 231 bp fragment of the LSAMP promoter contains one HhaI site, and digestion leads to
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Figure 4. Suppression of LSAMP, NORE1A, and
Nore1 re-expression on cell proliferation charac-
teristics
A: Re-expression and localization of EGFP-
LSAMP, -NORE1A, and -Nore1 fusion protein 2 hr
after microinjection or 24 hr after lipid-mediated
transfection of pEGFP-LSAMP, -NORE1A, and
-Nore1 plasmids.
B: Growth inhibition assay. A-498/Caki-1 cells
were microinjected with pEGFP-LSAMP, -NORE1A,
-Nore1, or pEGFP-C1/-N1 vector (negative con-
trol). Cell proliferation analysis was performed 2
hr after microinjection. Cells were counted at the
indicated times. The “proliferation index” on the
y axis represents the number of cells counted
at those times divided by the number of cells
counted 2 hr after injection.
that this nuclear Nore1 protein may not be a bona fide Ras studies of these genes may lead to the elucidation of novel
mechanisms of tumorigenesis.effector, whose family members tend to be lipid modified, mem-
brane bound positive regulators of cell proliferation. Further
Experimental proceduresinvestigation into its role in growth regulation (potentially through
the regulation of cyclin D1 and G1/S progression) and its role Family with CCRCC and t(1;3)(q32.1;q13.3), paired CCRCC
in the nucleus are needed. tumors/normal kidney tissues, and cell lines
Based on these data, LSAMP and NORE1A (a homolog of The clinical and genetic details of the Japanese kindred with familial CCRCC
have been previously published (Kanayama et al., 2001). The EBV-trans-3p21 tumor suppressor RASSF1A) may represent new tumor
formed lymphoblastoid cell lines FRCC3 and FRCC5 used in this study weresuppressor candidates and may act as components in the
established from two affected translocation carriers.
multistep process of CCRCC tumorigenesis. Inactivation or re- Four tumors were from three members of the t(1;3) family, and 53
duced expression of both LSAMP and NORE1A may be also matched pairs of CCRCC were collected from the University of Tokushima
in Japan.involved in the occurrence of other types of tumors. Further
fragments of 162 bp and 69 bp. Representative aberrant methylation of the LSAMP promoter in sporadic and familial CCRCC samples and in RCC cell
lines are shown.
C: Methylation analysis of the NORE1A promoter by restriction digestion with TaqI in the same cohort of samples. The examined 335 bp of the promoter
contains 35 CpG sequences. The methylated fragment contains two TaqI sites and digestion results in bands of 202, 123, and 10 bp. The sizes of molecular
weight markers (M) are shown on the left. N, normal kidney sample; T, RCC.
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